Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2331-2338

  Lehmann, Rainer ^a,b   Franken, Holger ^b   Dammeier, Sascha ^b   Rosenbaum, Lars ^b   Kantartzis, Konstantinos ^a,b   Peter, Andreas ^a,b   Zell, Andreas ^b   Adam, Patrick ^a   Li, Jia ^c   Xu, Guowang ^c   Königsrainer, Alfred ^b   Machann, Jürgen ^b   Schick, Fritz ^b   De Angelis, Martin Hrabé ^d   Schwab, Matthias ^b   Staiger, Harald ^a,b   Schleicher, Erwin ^a,b   Gastaldelli, Amalia ^e   Fritsche, Andreas ^a,b   Häring, Hans Ulrich ^a,b   Stefan, Norbert ^a,b   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CARNITINE; ISOLEUCINE; LEUCINE; LYSOPHOSPHATIDYLCHOLINE; ORNITHINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MALE; METABOLOMICS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; BLOOD; FATTY LIVER; LIVER; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84882959698     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1760     Document Type: Article

References (40)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-1523
2. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetesdpathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006;2:335-348
3. StefanN, Kantartzis K,HäringHU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960
4. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38
5. Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care 2009;32(Suppl. 2):S164-S167
6. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142: 711-725.e6
7. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506
8. Larson-Meyer DE, Newcomer BR, Ravussin E, et al. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia 2011;54:869-875
9. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-1616
10. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430-15435
11. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011;60:2011-2017
12. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:2616-2623
13. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-1288
14. Machann J, Thamer C, Stefan N, et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 2010;257:353-363
15. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing:comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
17. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
19. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
20. KronfeldM, Planatscher H, Zell A. Learning and intelligent optimization. Lect Notes Comput Sci 2010;6073:247-250
21. Franken H, Lehmann R, Häring HU, Fritsche A, Stefan N, Zell A. Wrapper- and ensemble-based feature subset selection methods for biomarker discovery in targeted metabolomics. In Pattern Recognition in Bioinformatics. Loog M, Wessels L, Reinders M, Ridder D, Eds. Berlin/Heidelberg, Springer, 2011, p. 121-132
22. Ressom HW, Varghese RS, Abdel-Hamid M, et al. Analysis ofmass spectral serumprofiles for biomarker selection. Bioinformatics 2005;21:4039-4045
23. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010;139:149-153
24. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
25. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678-1683
26. Würtz P, Mäkinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012;61: 1372-1380
27. Lattuada G, Sereni LP, Ruggieri D, et al. Postabsorptive and insulin-stimulated energy homeostasis and leucine turnover in offspring of type 2 diabetic patients. Diabetes Care 2004;27:2716-2722
28. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012;56:118-129
29. Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010;208:10-18
30. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012;28:159-165
31. Yea K, Kim J, Yoon JH, et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem 2009;284:33833-33840
32. Lin P, Welch EJ, Gao XP, Malik AB, Ye RD. Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J Immunol 2005; 174:2981-2989
33. Müller J, Petković M, Schiller J, Arnold K, Reichl S, Arnhold J. Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Luminescence 2002; 17:141-149
34. Hasegawa H, Lei J, Matsumoto T, Onishi S, Suemori K, Yasukawa M. Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun 2011;415:526-531
35. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18:363-374
36. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-859
37. Speletas M, Argentou N, Germanidis G, et al. Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 2011; 2011:827565
38. Peiseler M, Sebode M, Franke B, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012; 57:125-132
39. Gastaldelli A, Natali A, Gall WE, et al.; RISC investigators. Metabolomic profile associated with hepatic insulin resistance in nondiabetic subjects: results from the RISC Study. Diabetes 2012;61(Suppl. 1): A461
40. Fu S, Yang L, Li P, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 2011;473:528-531